Neurology

Verana Health and HealthVerity Partner to Advance Use of Real-World Evidence in Research

Data partnership initiative expands access to critical healthcare data in ophthalmology, urology and neurologySAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE)…

1 year ago

Smith+Nephew partners with HOPCo to provide AI-powered analytics and solutions to ASC customers

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes…

1 year ago

Compelling Research Supporting BrainCheck Presented at AAIC 2024 as Company Unveils New Brand Identity

New clinical data presented at world's largest forum for dementia research confirms BrainCheck Assess is as accurate as widely-used MoCA Refreshed…

1 year ago

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go…

1 year ago

Assure Announces Further Extension of Exchange Offer Relating to its Convertible Notes

DENVER, July 29, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (“Assure” or the “Company”) (NASDAQ: IONM), today announced that it has…

1 year ago

Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening…

1 year ago

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company…

1 year ago

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…

1 year ago

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and…

1 year ago